Skip to main content
Assets
Merck & logo
MRK.NYSE
Merck &
Health Care · Pharmaceuticals

Global healthcare company providing medicines and vaccines for oncology, vaccines, hospital acute care, and animal health including Keytruda.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Merck &.

Historical AI Opinions

Merck & Co., Inc. (MRK.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 11 advisor reports and comparisons.

Updated on 3 May 2026Deep analysis 3 May 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ThinkerAdvisor config deprecated
Warren Buffett AI advisor icon
Gemini 3 Pro

Warren Buffett AI

The Value Seeker Framework

Model rating

Strong Buy

5-Year Return Est.

+77.3%

Includes 1.68% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.60.894.11127.43160.75194.07Apr 2021Oct 2023Apr 2026Oct 2028May 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$117+4.0%
  • The Hormuz blockade and stagflationary macro environment drive intense flight-to-safety capital flows into inelastic healthcare assets.
  • Merck's Q2 earnings demonstrate complete immunity to the industrial and consumer spending slowdown.
  • Early benefits of domestic manufacturing resilience shine.
$120+7.1%
  • Keytruda and Gardasil post another quarter of mammoth cash generation.
  • Market begins to digest the Warsh Fed's 'higher for longer' rate reality, further punishing highly-levered tech while rewarding Merck's fortress balance sheet.
$125+11.4%
  • Positive early data on subcutaneous Keytruda formulation begins to shift the narrative away from the impending 2028 cliff.
  • Capital allocation shines as management announces disciplined share repurchases using excess cash.
$127+13.6%
  • Broad market stabilization slows the defensive rotation, but Merck grinds higher on sheer earnings execution.
  • Minor friction from FDA delays via the DOGE efficiency cuts slightly tempers pipeline enthusiasm.
$126+12.5%
  • Pre-cliff jitters begin to surface as sell-side analysts start issuing 2028 models highlighting the LOE revenue hole.
  • Mr. Market behaves irrationally, temporarily ignoring current cash flows to focus on future fears.
$130+15.9%
  • Management aggressively addresses 2028 fears during Q3 calls, detailing the pipeline bridge and ADC clinical progress.
  • Value investors step in to buy the temporary dip, recognizing the wide margin of safety.
$126+12.4%
  • The year of the LOE arrives. Narrative stress peaks.
  • Media headlines and 'dead money' sentiment dominate the stock, causing a mechanical sell-off despite underlying business health. This is the ultimate test of the patient owner.
$124+10.1%
  • Initial biosimilar entries hit the market outside the US, leading to early signs of pricing pressure on legacy Keytruda.
  • The stock searches for a floor as weak hands capitulate.
$130+15.7%
  • The turning point. Q2 earnings prove the cliff was a slope, not a sheer drop.
  • Subcutaneous uptake exceeds expectations, protecting the US revenue base.
  • Mr. Market realizes the doomsday scenario was wildly mispriced.
$138+22.6%
  • Pipeline validation hits hard. Major Phase 3 readouts for acquired immunology and ADC assets are highly positive.
  • The multiple explosively re-rates as the market officially looks past the LOE.
$142+26.3%
  • New product launches begin to actively replace lost Keytruda IV revenues.
  • Gardasil continues to compound, proving to be the unsung hero of the decade.
$147+31.3%
  • Earnings growth officially inflects positive again post-LOE.
  • Management leverages the pristine balance sheet to raise dividends significantly, rewarding patient capital.
$150+33.9%
  • Steady operational execution. The new oncology portfolio gains market share.
  • Minor regulatory frictions regarding global pricing limit upside slightly, but owner earnings compound.
$155+38.0%
  • Global macroeconomic stabilization favors high-quality compounders.
  • Merck cements its position as a diversified cardiometabolic and oncology powerhouse, no longer a single-asset story.
$159+42.1%
  • Operating margins expand as the R&D cycle from the mid-2020s M&A spree matures into high-margin commercial sales.
  • Free cash flow generation reaches new all-time highs.
$166+47.8%
  • The market fully recognizes Merck as a premier, wide-moat compounder.
  • Institutional capital heavily weights the stock for its predictability and highly ethical, shareholder-friendly capital allocation.
$169+50.7%
  • Routine quarterly performance. The business hums along with boring, beautiful predictability.
  • The moat is intact, and competitors struggle to unseat entrenched therapies.
$174+55.3%
  • Late-cycle pipeline assets enter trials, setting up the foundation for the 2030s.
  • Share count has been meaningfully reduced over the past five years, amplifying per-share intrinsic value.
$178+58.4%
  • Modest macro headwinds in the global economy present a minor drag, but inelastic demand protects the downside.
  • Dividend yields remain highly attractive relative to competing capital uses.
$183+63.1%
  • Five years out, the 2028 Keytruda panic is viewed as a historic buying opportunity.
  • Merck stands as a testament to the fact that wonderful businesses, bought at a margin of safety during times of crowd panic, yield tremendous owner returns.
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

I strongly believe that Merck is a wonderful business currently trading at a highly attractive price due to myopic fears. The Base Case envisions a steady grind upward as the defensive nature of the asset shines through the brutal 2026 macro shocks, followed by a manageable navigation of the 2028 cliff. The net effect of our drivers (inelastic demand, Gardasil growth, subcutaneous extension) vastly outweighs the frictions of the patent cliff and pricing pressures.

  • Near-term outperformance driven by flight-to-safety capital rotation during energy and geopolitical shocks.
  • Immense free cash flow generation from Keytruda funds smart, bolt-on biotechnology acquisitions.
  • Gardasil continues to compound at double-digits internationally, providing a non-oncology bedrock.
  • The 2028 LOE causes volatility and narrative stress, creating temporary price dips, but the fundamental cash destruction is less severe than modeled due to successful pipeline bridging.
  • Subcutaneous formulation secures at least 30% of the at-risk Keytruda revenue into the 2030s.
  • The implied market capitalization remains entirely realistic given the defensive premium assigned to elite healthcare assets in a volatile global money supply regime.

2. Scenarios & Signals

2.1. Bull Case

If the Base Case holds and our identified opportunities ignite, Merck becomes an unstoppable compounding machine. The market will awaken to find that the 'cliff' never materialized.

  • Subcutaneous Keytruda achieves near-total market conversion, utterly destroying the biosimilar bear thesis.
  • Recently acquired ADC and immunology assets read out with flawless Phase 3 data, securing best-in-class status.
  • The 'TrumpRx' reshoring incentives supercharge Merck's domestic manufacturing margins, turning regulatory pressure into a net positive.
  • The stock undergoes a massive multiple expansion as it sheds the 'patent cliff' discount and is repriced as a perpetual oncology monopoly.

2.2. Bear Case

In the event that management's capital allocation fails and macro pressures compound, owner economics will deteriorate. This is the scenario we demand a margin of safety to protect against.

  • The subcutaneous formulation fails to achieve significant clinical differentiation or market uptake, leaving the 2028 cliff fully exposed.
  • Key acquisitions like Prometheus fail in pivotal trials, representing billions in permanent capital destruction.
  • Global stagflation forces draconian government price controls across Europe and the US, structurally permanently impairing gross margins.
  • Merck enters a multi-year period of stagnant or declining owner's earnings as cash flow is entirely consumed by desperate, overpriced M&A.

2.3. Behavioral Alpha Signals

Sentiment, repricing cycle, crowd narrative, catalyst, and macro alignment.

Expected Volatility Regime

LowModerateHighExtreme

Greed and Fear Index

-100 Fear0+100 Greed
-45

Cycle Position

The reset is mostly complete and price drifts toward fair value.

EarlyAwareMomentumOvershootReversalCapit.StabilizeSTABILIZATION
Figure: Advisor position within the seven-stage market-recognition cycle. The highlighted point marks Stabilization.

What does Media Tell? (Crowd Consensus)

Mr. Market is currently obsessed with a single, highly visible narrative: the 2028 Keytruda patent cliff. The crowd treats Merck as a 'dead man walking', a one-trick pony whose golden goose is about to be slaughtered by biosimilars. Sell-side analysts are frantically modeling the revenue gap, largely ignoring the immense free cash flow being generated today, the defensive nature of the stock in a wartime economy, and the aggressive M&A pipeline replacement strategy currently underway.

What Crowds Get Wrong? (Alpha/Value Gap)

The variant perception here is stunningly simple: the market is mispricing the duration of the moat and undervaluing the cash generated *before* the cliff. By focusing entirely on 2028, the crowd is offering us Merck's massive, highly predictable 2026 and 2027 free cash flows at a discount. Furthermore, they assign near-zero probability to the success of the subcutaneous Keytruda formulation. This is classic time-horizon arbitrage; the market is paralyzed by an event two years out, allowing patient owners to acquire a fortress balance sheet and elite compounding machine at a wide margin of safety.

When will Value Gap Repricing Happen? (Repricing Catalyst)

The convergence will occur when Merck releases definitive Phase 3 data for its subcutaneous Keytruda formulation or newly acquired ADC pipeline assets, expected within the next 12-18 months. Once Mr. Market sees tangible proof that 2028 is a speed bump rather than a cliff, the valuation multiple will explosively revert to the mean.

How is Asset Influenced by Macro Regime?

The current macro regime of extreme geopolitical fragmentation, energy blockade shocks, and stagflation acts as a powerful tailwind for Merck. In a world where cyclical industrial and consumer discretionary earnings are highly vulnerable to Hormuz closures and supply chain collapse, Merck's inelastic healthcare revenues serve as an absolute fortress.

3. Positive & Negative Factors, Risks & Opportunities

3.1. Base-Case Forces

Near-certain positive forces

Top Drivers / Tailwinds

Structural or operating forces that support this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).

Scroll to view all columns

Top Drivers / Tailwinds with asset-specific estimated impacts and thesis rationale
Driver / TailwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
Subcutaneous Keytruda Franchise ExtensioInnovation And Product+15%Not quantifiedThe moat is wider than the bears think. Merck's aggressive push into a subcutaneous formulation of pembrolizumab threatens to extend their competitive advantage well into the 2030s. If approved and adopted, the switching costs for patients and providers become formidable, effectively neutralizing a significant portion of the biosimilar threat that the crowd assumes is a guaranteed death blow in 2028.
Ruthlessly Rational Capital AllocationCapital Allocation+14%Not quantifiedThis management team understands owner economics. Under CEO Rob Davis, Merck has not empire-built; they have ruthlessly acquired targeted biotechnology assets (like Prometheus and Harpoon) precisely to fortify the post-2028 pipeline. They are deploying the Keytruda windfall brilliantly, acquiring undervalued innovation while Mr. Market beats down the biotech sector under FDA/NIH efficiency cuts. This is exactly what you want a partner managing your family's savings to do.
Inelastic Health Demand FortressMacroeconomic And Macrofinancial+12%Not quantifiedI strongly believe that in a world tearing itself apart with blockades, energy shocks, and stagflation, true owner's earnings are found in inelastic demand. People will cut travel, dining, and discretionary spending to zero before they stop buying life-saving oncology and cardiometabolic therapeutics. Merck operates a business fundamentally insulated from the macroeconomic crosswinds of 2026; its cash flows are derived from biological necessity, not consumer confidence.
Keytruda CASH COW ResilienceCompetitive Positioning+10%Not quantifiedMr. Market is obsessively pricing in the 2028 Keytruda Loss of Exclusivity (LOE) cliff, entirely ignoring the colossal mountain of free cash flow this wide-moat asset will generate between now and then. Keytruda is one of the highest-grossing medicines in human history. The durability of these cash flows over the next two years provides management with immense capital to reinvest at high returns, creating a self-funding bridge to the next decade.

Near-certain negative forces

Top Frictions / Headwinds

Expected frictions that can slow, cap, or damage this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).

Scroll to view all columns

Top Frictions / Headwinds with asset-specific estimated impacts and thesis rationale
Friction / HeadwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
THE 2028 Keytruda Patent CliffCompetitive Positioning-15%Not quantifiedWe must be intellectually honest: the 2028 loss of exclusivity for Keytruda is a massive hurdle. Biosimilar competition will inevitably erode pricing power and margins for this specific asset. While I believe the market over-penalizes the stock today, the mechanical loss of high-margin monopoly revenue will serve as a severe gravitational pull on earnings growth during the cliff years.
Trumprx Pricing Margin CompressionRegulatory-8.0%Not quantifiedThe federal push for 'TrumpRx' and Most Favored Nation (MFN) pricing models undeniably limits pricing power. A business's moat is defined by its ability to raise prices without losing volume; government price-fixing artificially caps this power. This regulatory friction will structurally lower the terminal margin profile of the US pharmaceutical market.
FDA & NIH Bureaucratic ParalysisOperational Efficiency-6.0%Not quantifiedThe sweeping DOGE efficiency cuts at the FDA and NIH in early 2026 have slowed trial reviews and approval timelines. Time is the enemy of the drug developer. A slowed regulatory apparatus means delayed commercialization of the very pipeline assets Merck desperately needs to offset the Keytruda cliff, reducing the present value of those future cash flows.
Biotech Acquisition Overpayment RISKCapital Allocation-5.0%Not quantifiedDesperation breeds poor capital allocation. As 2028 approaches, management may feel intense pressure to plug the revenue hole, risking overpayment for late-stage biotech assets. If they abandon their valuation discipline and destroy shareholder capital by paying euphoric premiums for speculative science, owner economics will deteriorate rapidly.

3.2. Risks & Opportunities

Plausible downside scenarios

Tail Risks

Less likely downside scenarios that could materially hurt the outcome if they occur.

Scroll to view all columns

Tail risks with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
Pipeline Clinical Failure Cascade25%-30%The ultimate nightmare for a value owner is permanent capital impairment. If Merck's key acquired assets (like Prometheus's immunology compound) fail spectacularly in late-stage trials, the billions spent on M&A will be written off, and the 2028 Keytruda cliff will arrive with no safety net, destroying massive intrinsic value.
Draconian Global Price Controls20%-25%Should the US 'TrumpRx' model trigger a synchronized global wave of aggressive, punitive price-fixing across Europe and Asia as sovereign governments reel from energy-induced fiscal crises, the baseline economics of pharmaceutical innovation would be permanently impaired. The moat would be legislated out of existence.

Plausible upside scenarios

Tail Opportunities

Less likely upside scenarios that could materially improve the outcome if they occur.

Scroll to view all columns

Tail opportunities with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
Subcutaneous Keytruda Total Conversion40%+25%If Merck successfully transitions the vast majority of its Keytruda patient base to the new subcutaneous formulation before 2028, it will effectively rebuild the moat right as the drawbridge is lowering. This would annihilate the bear thesis, preserving tens of billions in high-margin cash flows that the market currently models as evaporating.
ADC Pipeline Blockbuster Validation30%+20%Merck has heavily invested in Antibody-Drug Conjugates (ADCs) through partnerships and M&A. Should Phase 3 data in the next two years prove these assets to be best-in-class standard-of-care replacements in solid tumors, the market will instantly re-rate Merck from a 'dying patent' story to an 'enduring oncology monopoly' story.

5. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 72,300Thinking Tokens: 2,394Response Tokens: 4,978Total Tokens: 79,672
Thinker modeThinker · no external search

This Thinker run did not use external web search. The model relied on the supplied research context and its internal reasoning.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    inmemory_base_placeholders__latest_eod_close_price_with_stats__var2

  2. 02

    Global context in this run

    Used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Subject context

    Equity-specific subject and market context

  5. 05

    Global context

    Standard global market and cross-asset context

  6. 06

    Task framework

    Standard investment-forecast task guidelines

  7. 07
    Warren Buffett AI advisor icon

    Advisor framework

    Warren Buffett The Value Seeker

  8. 08

    Forecast output requested

    Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

03

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

File size
90.8K bytes
Words
12.8K words
Characters
90.8K characters

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From FileDateStatus
DeepSeek shock and AI economics reset2025-01-27OPEN ENDED TREND
US tariff regime escalation and trade-system rupture2025-02-01ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold2025-09-17ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal ReserveUS Bureau of Labor StatisticsUS Bureau of Economic AnalysisUS TreasuryUS Energy Information AdministrationReuters WorldAssociated Press World NewsBBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market Context through 2026-04-10

Download Archived Snapshot

Coverage 2026-01-01 to 2026-04-10 · Knowledge cutoff 2026-04-10

File size
73.5K bytes
Words
9.8K words
Characters
73.5K characters

This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-04-10.

It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.

Top 3 market shifts from 2026 Year-to-Date Global Market Context through 2026-04-10
Top 3 Market Shifts From FileDateStatus
The Iran and Strait of Hormuz conflict shocked energy markets2026-02-28STARTED AND ONGOING
U.S. monetary policy entered the Warsh transition2026-01-30STARTED AND ACTIVE POLICY TRANSITION
Agentic AI and infrastructure spending kept expanding2026-01-01OPEN ENDED

Representative Sources of the Context File

Federal ReserveU.S. Bureau of Labor StatisticsU.S. Bureau of Economic AnalysisU.S. TreasuryU.S. Energy Information AdministrationReutersAssociated PressBBC News

And more sources from the retained context package.

02

Fundamental context

annual: 0 periods; quarterly: 0 periods

Currencies cited: USD (quote USD).

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.